Latest News

Neda Shamie, MD, recounts a humbling experience performing cataract surgery in Honduras using older-generation phaco machines, revealing how technology elevates both skill and patient care.

Roundtable discussion explores surgical and sustained-release options.

The Special Meeting of Stockholders that was scheduled for October 23, 2025 has been delayed to November 6, 2025.

Chiu discusses factors affecting adoption of the FDA-approved epi-on therapy, from clinic setup to insurance coverage, while highlighting its safety and efficacy.

REMAIN is the long-term extension of the phase 2b/3 RESTORE trial evaluating MCO-010 in retinitis pigmentosa (RP).

The decision follows results from the Phase 3 STAR trial, among the largest global studies of low-dose atropine in pediatric myopia.

Innovations in surgery, biologics, and AI are shaping the future of eye aesthetics.

Their discussion sheds light on the importance of physician advocacy in ophthalmology—from shaping policy and protecting patients to building community.

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.

Inder Paul Singh, MD, shares a formative experience in which a patient’s vision loss—and their unexpected gesture of comfort—shaped his approach to high-risk glaucoma care.

A study reveals that systemic chemotherapy significantly reduces mortality in retinoblastoma, while targeted treatments lower enucleation rates.

How pupil modulation and pharmacologic targeting shape near vision outcomes.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk